List of investigational eating disorder drugs

This is a list of investigational eating disorder drugs, or drugs that are currently under development for clinical use for the treatment of eating disorders but are not yet approved. Eating disorders include anorexia nervosa, bulimia nervosa, and binge-eating disorder, among others. This page does not include drugs under development for treatment of overweightness/obesity (excessive appetite) or anorexia (low appetite).

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]".

This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Phase 3

• Armodafinil ((R)-modafinil; CEP-10953; Nuvigil) – atypical dopamine reuptake inhibitor (DRI) – eating disorders https://adisinsight.springer.com/drugs/800022302
• Solriamfetol (ADX-N05; ARL-N05; JZP-110; SKL-N05; Sunosi) – norepinephrine–dopamine reuptake inhibitor (NDRI) – binge-eating disorder https://adisinsight.springer.com/drugs/800030225

Phase 2

• BP-14979 (BP-1.4979; BP1-4979) – dopamine D₃ receptor partial agonist – binge-eating disorder https://adisinsight.springer.com/drugs/800037563
• Lidocaine (ORE-001) – sodium channel blocker – anorexia nervosa https://adisinsight.springer.com/drugs/800074357
• Naloxone nasal spray (LT-12; LT-20; LT-21; LT-22; Naloxon B; Narcan nasal spray; OPNT-001) – μ-opioid receptor antagonist – eating disorders https://adisinsight.springer.com/drugs/800034186
• Nivasorexant (ACT-539313; SORA) – orexin OX₁ receptor antagonist – binge-eating disorder https://adisinsight.springer.com/drugs/800049623
• Oxytocin (intranasal potentiated oxytocin; TI-001; TI-114; TNX-1900; TNX-2900) – oxytocin receptor agonist – binge-eating disorder https://adisinsight.springer.com/drugs/800031615
• Psilocybin (COMP-360; COMP360) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – anorexia nervosa https://adisinsight.springer.com/drugs/800050861
• Psilocybin (PFN™; TRP-8802; TRP-8803; TRP-8804; TRYP-0082) – non-selective serotonin receptor agonist, serotonin 5-HT_2A receptor agonist, and serotonergic psychedelic – binge-eating disorder https://adisinsight.springer.com/drugs/800060245
• Vortioxetine (Brintellix; LU-AA21004; LuAA 21004; Trintellix; Vortidif) – serotonin reuptake inhibitor, serotonin 5-HT_1A and 5-HT_1B receptor agonist, and serotonin 5-HT_1D, 5-HT₃, and 5-HT₇ receptor antagonist – binge-eating disorder https://adisinsight.springer.com/drugs/800020088

Phase 1

• CVN-766 (CVN766) – orexin OX₁ receptor antagonist – binge-eating disorder https://adisinsight.springer.com/drugs/800066143

Preclinical

• Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABA_A receptor positive allosteric modulator) – eating disorders https://adisinsight.springer.com/drugs/800029334
• TACT411 – serotonin 5-HT_1B receptor modulator and monoamine transporter modulator – anorexia nervosa, binge-eating disorder
• TACT523 – undefined mechanism of action – anorexia nervosa, binge-eating disorder
• TACT833 – serotonin 5-HT_1B receptor modulator and monoamine transporter modulator – anorexia nervosa, binge-eating disorder

Not under development

No development reported

• BMB-101 (BMB101) – serotonin 5-HT_2C receptor agonist – binge-eating disorder https://adisinsight.springer.com/drugs/800065004
• GSK-598809 (GSK598809) – dopamine D₃ receptor antagonist – eating disorders https://adisinsight.springer.com/drugs/800025964
• Ibogaine – various actions – anorexia nervosa
• Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – binge-eating disorder https://adisinsight.springer.com/drugs/800069916
• Mescaline (BMND-04/BMND04) – non-selective serotonin receptor agonist and psychedelic hallucinogen – eating disorders
• Olanzapine (BR-5402; LY-170053; LY-170052; Midax; Zypadhera; Zyprexa) – atypical antipsychotic (non-selective monoamine receptor modulator) – anorexia nervosa https://adisinsight.springer.com/drugs/800001477
• Psilocybin (PSY-0.1, PSY-0.2, PSY-0.3, PSY-0.4/0.5, PSY-0.6) – non-selective serotonin receptor agonist and psychedelic hallucinogen – eating disorders

Discontinued

• Amphetamine modified release (HLD-900; HLD-100) – norepinephrine–dopamine releasing agent (NDRA) – bulimia nervosa https://adisinsight.springer.com/drugs/800038292
• Centanafadine (CTN-SR; EB-1020) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – binge-eating disorder https://adisinsight.springer.com/drugs/800035830
• Dasotraline (DSP-225289; SEP-225289; SEP-0225289; SEP-289) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – binge-eating disorder https://adisinsight.springer.com/drugs/800023450
• Femoxetine (femoxitine; FG-4963; Malexil; NNC-204963) – selective serotonin reuptake inhibitor (SSRI) – eating disorders https://adisinsight.springer.com/drugs/800000721
• Ghrelin synthetic (OXE-103; SUN-11031) – ghrelin receptor agonist – anorexia nervosa https://adisinsight.springer.com/drugs/800043484
• GW-181771 (GI-181771; GSKI-181771X) – cholecystokinin CCK_A receptor agonist – bulimia nervosa https://adisinsight.springer.com/drugs/800013294
• Meclinertant (reminertant; SR-48692) – neurotensin NTS₁ receptor antagonist – anorexia nervosa https://adisinsight.springer.com/drugs/800002937
• Naloxone nasal spray (LT-12; LT-20; LT-21; LT-22; Naloxon B; Narcan nasal spray; OPNT-001) – μ-opioid receptor antagonist – bulimia nervosa https://adisinsight.springer.com/drugs/800034186
• Samidorphan (ALKS-33; RDC-0313; RDC-0313-00) – μ-opioid receptor antagonist – eating disorders https://adisinsight.springer.com/drugs/800029336
• Sertraline (Aremis; Besitran; CP-51974; CP-51974-01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) – night eating syndrome https://adisinsight.springer.com/drugs/800006147
• Tandospirone (metanopirone; Sediel; SM-3997) – serotonin 5-HT_1A receptor agonist – eating disorders https://adisinsight.springer.com/drugs/800000567
• Ticalopride ((+)-norcisapride) – serotonin 5-HT₃ receptor antagonist, serotonin 5-HT₄ receptor agonist – bulimia nervosa https://adisinsight.springer.com/drugs/800007174 https://synapse.patsnap.com/drug/d9e10d6684a845f589e390179297bbbb

Clinically used drugs

Approved drugs

• Dronabinol (tetrahydrocannabinol; THC; Δ₉-THC; Deltanyne; Elevat; Marinol; NSC-134454) – cannabinoid CB₁ and CB₂ receptor agonist – anorexia nervosa https://adisinsight.springer.com/drugs/800007811
• Fluoxetine (LY-110140; Prozac; Reneuron; Sarafem) – selective serotonin reuptake inhibitor (SSRI) – bulimia nervosa https://adisinsight.springer.com/drugs/800013380
• Fluoxetine – selective serotonin reuptake inhibitor (SSRI) – bulimia nervosa https://adisinsight.springer.com/drugs/800042922
• Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – eating disorders https://adisinsight.springer.com/drugs/800020876

See also

• Lists of investigational drugs

References

External links

• AdisInsight - Springer